Please login to the form below

Not currently logged in
Email:
Password:

HM71224

This page shows the latest HM71224 news and features for those working in and with pharma, biotech and healthcare.

Lilly drops Hanmi-partnered arthritis drug

Lilly drops Hanmi-partnered arthritis drug

Eli Lilly has decided to abandon trials of its BTK inhibitor HM71224 in rheumatoid arthritis after an interim look at its prospects. ... Lilly licensed HM71224 (LY3337641) from South Korean biotech Hanmi Pharmaceutical in 2015 for $50m upfront and

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics